The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study
Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐keta...
Gespeichert in:
Veröffentlicht in: | Acta anaesthesiologica Scandinavica 2024-11, Vol.68 (10), p.1359-1368 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1368 |
---|---|
container_issue | 10 |
container_start_page | 1359 |
container_title | Acta anaesthesiologica Scandinavica |
container_volume | 68 |
creator | Nielsen, Bettina N. Henneberg, Steen W. Olsson, Eva Malmros Lundeberg, Stefan |
description | Background
Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room.
Objective(s)
The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use.
Design
Retrospective observational study.
Setting
Tertiary care paediatric hospital.
Patients
Children 1 year up till 18 years.
Intervention(s)
Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK).
Main Outcome Measure(s)
The frequency of adverse events including serious adverse events reported by intervention.
Results
Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK.
Conclusions
Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff. |
doi_str_mv | 10.1111/aas.14510 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3094472522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120167776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</originalsourceid><addsrcrecordid>eNp1kcuKFDEYhYMoTju68AUk4EYXNZ1LVaXLXTN4gwEXjuviT_LHyViVanMZ6Z2P4Bv4bj6J6enRhWAI5ML3H87hEPKUszNe1xognfG24-weWXE5DE3fqf4-WTHGeNNxJU7Io5Su61O2w_CQnMiBd123YSvy8_IKaUlIF0d9yBECJJhoKg5DhuAnCsGul0jTr-8_vmCG2Qekrn7kiJDnSh1Gd3ExaEusozvwoUpRc-UnG_H2DnXPukyQl7inCXP24fMruqURc1zSDk32N9WDThhvIPslHDzkYvePyQMHU8Ind-cp-fTm9eX5u-biw9v359uLxgi1YQ2CqMG53Wghe9Doho4bpwboEbkVTncanJVCWGtka3QLrbPaSei1Fr1T8pS8OOrWJF8LpjzOPhmcJgi4lDRKNrStEp0QFX3-D3q9lFgdV4oLxnulVF-pl0fK1IApoht30c8Q9yNn46G1sbY23rZW2Wd3ikXPaP-Sf2qqwPoIfPMT7v-vNG63H4-SvwEpoKY2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120167776</pqid></control><display><type>article</type><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</creator><creatorcontrib>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</creatorcontrib><description>Background
Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room.
Objective(s)
The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use.
Design
Retrospective observational study.
Setting
Tertiary care paediatric hospital.
Patients
Children 1 year up till 18 years.
Intervention(s)
Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK).
Main Outcome Measure(s)
The frequency of adverse events including serious adverse events reported by intervention.
Results
Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK.
Conclusions
Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</description><identifier>ISSN: 0001-5172</identifier><identifier>ISSN: 1399-6576</identifier><identifier>EISSN: 1399-6576</identifier><identifier>DOI: 10.1111/aas.14510</identifier><identifier>PMID: 39155580</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>acute pain ; Administration, Intranasal ; Adolescent ; Adverse events ; Ambulatory Care ; Analgesics ; Analgesics - administration & dosage ; Analgesics - therapeutic use ; Bronchospasm ; Child ; Child, Preschool ; Children ; Complications ; Developmental disabilities ; Female ; Humans ; Infant ; intranasal ; Ketamine ; Ketamine - administration & dosage ; Ketamine - adverse effects ; Ketamine - therapeutic use ; Male ; Medical procedures ; Observational studies ; Pain ; Pain, Procedural - etiology ; Pain, Procedural - prevention & control ; Patients ; Pediatrics ; Retrospective Studies ; Seizures ; Sufentanil ; Sufentanil - administration & dosage ; Sufentanil - adverse effects ; s‐ketamine</subject><ispartof>Acta anaesthesiologica Scandinavica, 2024-11, Vol.68 (10), p.1359-1368</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2024 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</cites><orcidid>0000-0003-2273-2942 ; 0000-0001-9893-890X ; 0000-0002-6576-623X ; 0000-0001-7848-4752</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faas.14510$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faas.14510$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39155580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nielsen, Bettina N.</creatorcontrib><creatorcontrib>Henneberg, Steen W.</creatorcontrib><creatorcontrib>Olsson, Eva Malmros</creatorcontrib><creatorcontrib>Lundeberg, Stefan</creatorcontrib><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><title>Acta anaesthesiologica Scandinavica</title><addtitle>Acta Anaesthesiol Scand</addtitle><description>Background
Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room.
Objective(s)
The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use.
Design
Retrospective observational study.
Setting
Tertiary care paediatric hospital.
Patients
Children 1 year up till 18 years.
Intervention(s)
Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK).
Main Outcome Measure(s)
The frequency of adverse events including serious adverse events reported by intervention.
Results
Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK.
Conclusions
Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</description><subject>acute pain</subject><subject>Administration, Intranasal</subject><subject>Adolescent</subject><subject>Adverse events</subject><subject>Ambulatory Care</subject><subject>Analgesics</subject><subject>Analgesics - administration & dosage</subject><subject>Analgesics - therapeutic use</subject><subject>Bronchospasm</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Complications</subject><subject>Developmental disabilities</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>intranasal</subject><subject>Ketamine</subject><subject>Ketamine - administration & dosage</subject><subject>Ketamine - adverse effects</subject><subject>Ketamine - therapeutic use</subject><subject>Male</subject><subject>Medical procedures</subject><subject>Observational studies</subject><subject>Pain</subject><subject>Pain, Procedural - etiology</subject><subject>Pain, Procedural - prevention & control</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Seizures</subject><subject>Sufentanil</subject><subject>Sufentanil - administration & dosage</subject><subject>Sufentanil - adverse effects</subject><subject>s‐ketamine</subject><issn>0001-5172</issn><issn>1399-6576</issn><issn>1399-6576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kcuKFDEYhYMoTju68AUk4EYXNZ1LVaXLXTN4gwEXjuviT_LHyViVanMZ6Z2P4Bv4bj6J6enRhWAI5ML3H87hEPKUszNe1xognfG24-weWXE5DE3fqf4-WTHGeNNxJU7Io5Su61O2w_CQnMiBd123YSvy8_IKaUlIF0d9yBECJJhoKg5DhuAnCsGul0jTr-8_vmCG2Qekrn7kiJDnSh1Gd3ExaEusozvwoUpRc-UnG_H2DnXPukyQl7inCXP24fMruqURc1zSDk32N9WDThhvIPslHDzkYvePyQMHU8Ind-cp-fTm9eX5u-biw9v359uLxgi1YQ2CqMG53Wghe9Doho4bpwboEbkVTncanJVCWGtka3QLrbPaSei1Fr1T8pS8OOrWJF8LpjzOPhmcJgi4lDRKNrStEp0QFX3-D3q9lFgdV4oLxnulVF-pl0fK1IApoht30c8Q9yNn46G1sbY23rZW2Wd3ikXPaP-Sf2qqwPoIfPMT7v-vNG63H4-SvwEpoKY2</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Nielsen, Bettina N.</creator><creator>Henneberg, Steen W.</creator><creator>Olsson, Eva Malmros</creator><creator>Lundeberg, Stefan</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2273-2942</orcidid><orcidid>https://orcid.org/0000-0001-9893-890X</orcidid><orcidid>https://orcid.org/0000-0002-6576-623X</orcidid><orcidid>https://orcid.org/0000-0001-7848-4752</orcidid></search><sort><creationdate>202411</creationdate><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><author>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>acute pain</topic><topic>Administration, Intranasal</topic><topic>Adolescent</topic><topic>Adverse events</topic><topic>Ambulatory Care</topic><topic>Analgesics</topic><topic>Analgesics - administration & dosage</topic><topic>Analgesics - therapeutic use</topic><topic>Bronchospasm</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Complications</topic><topic>Developmental disabilities</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>intranasal</topic><topic>Ketamine</topic><topic>Ketamine - administration & dosage</topic><topic>Ketamine - adverse effects</topic><topic>Ketamine - therapeutic use</topic><topic>Male</topic><topic>Medical procedures</topic><topic>Observational studies</topic><topic>Pain</topic><topic>Pain, Procedural - etiology</topic><topic>Pain, Procedural - prevention & control</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Seizures</topic><topic>Sufentanil</topic><topic>Sufentanil - administration & dosage</topic><topic>Sufentanil - adverse effects</topic><topic>s‐ketamine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, Bettina N.</creatorcontrib><creatorcontrib>Henneberg, Steen W.</creatorcontrib><creatorcontrib>Olsson, Eva Malmros</creatorcontrib><creatorcontrib>Lundeberg, Stefan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta anaesthesiologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, Bettina N.</au><au>Henneberg, Steen W.</au><au>Olsson, Eva Malmros</au><au>Lundeberg, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</atitle><jtitle>Acta anaesthesiologica Scandinavica</jtitle><addtitle>Acta Anaesthesiol Scand</addtitle><date>2024-11</date><risdate>2024</risdate><volume>68</volume><issue>10</issue><spage>1359</spage><epage>1368</epage><pages>1359-1368</pages><issn>0001-5172</issn><issn>1399-6576</issn><eissn>1399-6576</eissn><abstract>Background
Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room.
Objective(s)
The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use.
Design
Retrospective observational study.
Setting
Tertiary care paediatric hospital.
Patients
Children 1 year up till 18 years.
Intervention(s)
Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK).
Main Outcome Measure(s)
The frequency of adverse events including serious adverse events reported by intervention.
Results
Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK.
Conclusions
Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39155580</pmid><doi>10.1111/aas.14510</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2273-2942</orcidid><orcidid>https://orcid.org/0000-0001-9893-890X</orcidid><orcidid>https://orcid.org/0000-0002-6576-623X</orcidid><orcidid>https://orcid.org/0000-0001-7848-4752</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0001-5172 |
ispartof | Acta anaesthesiologica Scandinavica, 2024-11, Vol.68 (10), p.1359-1368 |
issn | 0001-5172 1399-6576 1399-6576 |
language | eng |
recordid | cdi_proquest_miscellaneous_3094472522 |
source | MEDLINE; Access via Wiley Online Library |
subjects | acute pain Administration, Intranasal Adolescent Adverse events Ambulatory Care Analgesics Analgesics - administration & dosage Analgesics - therapeutic use Bronchospasm Child Child, Preschool Children Complications Developmental disabilities Female Humans Infant intranasal Ketamine Ketamine - administration & dosage Ketamine - adverse effects Ketamine - therapeutic use Male Medical procedures Observational studies Pain Pain, Procedural - etiology Pain, Procedural - prevention & control Patients Pediatrics Retrospective Studies Seizures Sufentanil Sufentanil - administration & dosage Sufentanil - adverse effects s‐ketamine |
title | The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20intranasal%20sufentanil%20and/or%20s%E2%80%90ketamine%20for%20treatment%20of%20procedural%20pain%20in%20children%20in%20an%20ambulatory%20setting:%20A%20retrospective%20observational%20study&rft.jtitle=Acta%20anaesthesiologica%20Scandinavica&rft.au=Nielsen,%20Bettina%20N.&rft.date=2024-11&rft.volume=68&rft.issue=10&rft.spage=1359&rft.epage=1368&rft.pages=1359-1368&rft.issn=0001-5172&rft.eissn=1399-6576&rft_id=info:doi/10.1111/aas.14510&rft_dat=%3Cproquest_cross%3E3120167776%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3120167776&rft_id=info:pmid/39155580&rfr_iscdi=true |